内容概要：随着国家政策的推动，以及配套产业链的技术成熟，国内血型检测仪器企业逐步提升技术核 心竞争力并对产品创新升级，已突破多项技术壁垒，使得血型检测产业得到快速发展。国内全自动血型 检测仪器产品已覆盖微孔板法、微柱凝胶法等国际主流检测方法，能够提供高度自动化、标准化的血型 检测流程，在临床输血中担任着重要角色。中国血型检测设备市场规模由2018年的8.85亿元提升至2024 年17.04亿元，期间实现年复合增长率为11.5%。由于血型检测的检测特性及一次性用品的高消耗性，其 市场主要由试剂及检测试剂盒的销售所推动，占总市场规模超80%，2024年中国血型检测试剂产品市场 规模为13.81亿元，同比增长11.9%。其余则归因于设备销售，2024年设备市场规模为3.23亿元，同比增 长10.6%。血型检测设备与试剂堪称基础且关键的存在，输血治疗、器官移植等医疗手段，都离不开精 准血型检测的支撑。近年来，众多国产厂家强势崛起，在技术创新、市场份额拓展等方面开花，逐渐改 写市场竞争格局。本土企业中，2024年，长春博迅凭借其在血型检测领域的先进技术和丰富经验，占据 了21%的市场份额，麦科田市占率为3.9%。ORT ...

Core Insights - High-end medical devices are considered "national treasures" and are important indicators of a country's manufacturing capabilities and technological development [1] - Shenzhen is a hub for high-end medical device manufacturing, home to notable companies like Mindray Medical, BGI, and New Industries, as well as many "invisible champions" in niche markets [1] Company Overview - Aikang Bio is a high-tech enterprise specializing in the research and production of blood testing and preparation equipment, with its core products, the fully automated enzyme immunoassay instrument and blood type analyzer, holding the top market share in several niche areas [1] - The company emphasizes quality control and timely delivery by developing and manufacturing most of its components in-house, with thousands of self-produced parts available [1] Business Strategy - Aikang Bio prioritizes the value of its niche market over immediate profits, believing that if they do not engage in certain production processes, no other companies will [2] - The company benefits from Shenzhen's advanced manufacturing supply chain and strong government support, which alleviates operational concerns [2] - Aikang Bio's strategy focuses on refining products and enhancing service quality, which has allowed it to grow from a small office in Huaqiangbei to a headquarters in Pingshan [2] - The company is also developing new products aimed at the global market to address the limitations of its niche industry [2]